<?xml version="1.0" encoding="UTF-8"?>
<AssessmentQuestion xmlns="http://soap.sforce.com/2006/04/metadata">
    <assessmentQuestionVersion>
        <isActive>true</isActive>
        <name>AHUS_Initial_First_Presentation_of_Recurrent_Q1</name>
        <optionSourceResponseValue>false</optionSourceResponseValue>
        <questionText>Approval requires a confirmed diagnosis of aHUS with an unacceptably high risk of relapse.  All of criteria 1, 2 and 3 must be met.  Approval is for 6 months only.  After eculizumab withdrawal, we suggest the monitoring strategy noted below, and approval for one urgent dose will be provided in the event of relapse with further coverage requiring completion of the Post-Transplant Recurrence application form.</questionText>
        <status>Active</status>
        <versionNumber>2</versionNumber>
    </assessmentQuestionVersion>
    <dataType>TextBlock</dataType>
    <developerName>AHUS_Initial_First_Presentation_of_Recurrent_Q1</developerName>
    <name>AHUS_Initial_First_Presentation_of_Recurrent_Q1</name>
    <questionCategory>Demographic</questionCategory>
</AssessmentQuestion>
